Mark Titus
Associate Professor
The University of Texas MD Anderson Cancer Center
Department of Genitourinary Medical Oncology
The research focus of my laboratory is to understand the impact of altered intracrine and endocrine steroid biosynthesis on paracrine and autocrine androgen signaling in prostate cancer. We are currently studying steroidogenesis enzymes, receptor proteins and second-generation androgen signaling inhibitors (ASI) Zytiga and Xtandi that modulate cholesterol and steroid nuclear receptor ligand biosynthesis. To test for mechanisms of resistance to ASI, ASI combinations, and ASI and cytotoxic therapies we use unique tissue culture cell line models and human derived advanced and metastatic prostate cancer xenografts. We have also established analytical and biochemical assays to measure steroid, fatty acid and energy metabolite profiles that support tumor cell survival and proliferation.
My laboratory collaborates with clinicians performing prostate cancer chemoprevention and hormone intervention clinical trials. We determine small molecule profiles using human plasma, serum, bone marrow aspirate and tissue bio-specimens collected during hormone therapy. Our quantitative pharmacometabolome analysis of model systems, and liquid and tissue biopsies contribute to a multicomponent androgen axis biomarker panel that categorize and direct ASI therapy. Overall, our laboratory and clinical investigations will translate to precision therapy and personalized healthcare for prostate cancer patients.
A tutorial in my laboratory will provide experience in analytical chemistry and biochemistry techniques used to study prostate cancer tumor progression, metastasis, biomarker identification and small molecule imaging targets.
Education & Training
Ph.D. - University of Washington - 1998